You are here

Positive Phase III Results With Simeprevir in Hepatitis Patients

NDA submitted for treatment of genotype 1 hepatitis C (May 21)

Positive results have been reported from the global phase III PROMISE trial, which compared the investigational protease inhibitor simeprevir (TMC435; Janssen R&D Ireland), administered once daily with pegylated interferon (peg-IFN) and ribavirin, with placebo plus peg-IFN and ribavirin in treatment-experienced genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis.

Simeprevir plus peg-IFN and ribavirin achieved a sustained virologic response 12 weeks after the end of treatment (SVR12) in 79% of patients, compared with 37% of patients receiving placebo plus peg-IFN and ribavirin.

In the simeprevir arm, the on-treatment failure rate was 3% and the relapse rate was 19%, compared with 27% and 48%, respectively, in the placebo arm. All of the patients had previously relapsed following peg-IFN–based therapy.

The new findings were presented May 21 at the Digestive Disease Week 2013 conference in Orlando, Florida.

Patients enrolled in the PROMISE trial were stratified by hepatitis C virus (HCV) genotype 1 subtype and IL28B genotype. SVR12 rates among patients treated with simeprevir according to IL28B genotype were 89% for the CC allele, 78% for the CT allele, and 65% for the TT allele, compared with 53%, 34%, and 19%, respectively, in the placebo arm.

The most common adverse events observed in patients receiving simeprevir versus placebo included fatigue (32% vs. 42%, respectively), headache (32% vs. 36%), and influenza-like illness (30% vs. 20%).

Simeprevir is an investigational NS3/4A protease inhibitor developed for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including all stages of liver fibrosis. The drug works by blocking the protease enzyme that enables HCV to replicate in host cells. A new drug application (NDA) was recently submitted for simeprevir for the treatment of genotype 1 hepatitis C.

Source: Johnson & Johnson; May 21, 2013.

Recent Headlines

Citrus, Berries, Broccoli Reduce Risk of Cancer and CVD
Changes in Antibiotic Recommendations for Children
Influences Gene Involved in Circadian Rhythms
‘The Perfect Drug for Trauma-Focused Psychotherapy’
Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients